Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Deutsche Reiterates Sell on Biogen Idec


Deutsche Bank reiterates sell on Biogen Idec (BIIB) and cuts target.

Analyst Jennifer Chao estimates it could take several months just to compile and sift through patient data, complete challenging technical/statistical analysis, all of which are subject to careful regulatory review.

Given the complex nature of the review, she doesn't expect meaningful updates in the near- to medium-term. She recommends investors stay on sidelines until visibility on Tysabri justifies signficant risks.

Chao cuts her $38 target to $33, 19 times $1.73 2006 earnings per share. She believes her 19 multiple is justified as uncertainty related to Tysabri could cause Biogen Idec shares to languish.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus